MedTrace Logo

Phase 1 Study of SBS-147 in Healthy Adults

NCT07335913 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-03-03

No results posted yet for this study

Summary

This study is part of the HEAL Initiative supported by the NIH.

The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147.

Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results.

The study includes two parts:

Single-Dose Group, where Participants receive SBS-147 or placebo one time.

Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Conditions

Interventions

DRUG

SBS-147

Experimental therapeutic

DRUG

Placebo

Placebo comparator

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Altasciences Company Inc.

    collaborator INDUSTRY

  • Sparian Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Jeff Reich, MD · Sparian Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-08
Primary Completion
2027-01-31
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07335913 on ClinicalTrials.gov